Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)
Status:
Completed
Trial end date:
2016-12-06
Target enrollment:
Participant gender:
Summary
This is a multi-centre, double blind, double dummy, randomised, controlled study to evaluate
the efficacy and safety of TDF 300mg QD versus ADV 10mg QD in Chinese subjects with CHB. This
study is designed to demonstrate the superiority of TDF 300mg QD over ADV 10mg QD in treating
Chinese subjects with CHB (hepatitis B e antigen [HBeAg] positive subjects and HBeAg negative
subjects). It will also provide long-term efficacy and safety data (up to 240 weeks) for TDF
300 mg administered once daily.